文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

泰地唑胺单药与莫西沙星联合治疗儿童胞内结核模型的多参数应答

Multiparameter Responses to Tedizolid Monotherapy and Moxifloxacin Combination Therapy Models of Children With Intracellular Tuberculosis.
PubMed 文献 · Clin Infect Dis · 2018-01-01

本研究在胞内结核中空纤维系统模型中开展泰地唑胺剂量效应研究,检测利奈唑胺浓度、菌落形成单位、至阳性时间及单核细胞活力,并对感染细胞进行RNA测序。结果显示泰地唑胺无抑制线粒体酶基因下调,高暴露反而增加线粒体基因表达和单核细胞存活,且EC80杀菌效果比利奈唑胺高4.0 log10 CFU/mL;泰地唑胺-莫西沙星联合的细菌负担消除速率常数为0.27±0.05/天。

要点

  • 泰地唑胺在胞内结核模型中无利奈唑胺样线粒体毒性基因特征。
  • 泰地唑胺EC80杀菌效果比利奈唑胺高4.0 log10 CFU/mL。
  • 泰地唑胺-莫西沙星联合细菌消除速率常数为0.27±0.05/天。

核心结论

  • 泰地唑胺比利奈唑胺更有效,且未出现线粒体毒性基因或细胞毒性特征。
  • 泰地唑胺-莫西沙星联合具有高细菌消除速率。

研究设计与样本

  • 在胞内结核中空纤维系统模型中开展泰地唑胺剂量效应研究。
  • 检测利奈唑胺浓度、菌落形成单位(CFU)、至阳性时间、单核细胞活力,并对感染细胞进行RNA测序。
  • 比较泰地唑胺与利奈唑胺及泰地唑胺-莫西沙星联合的疗效。

主要发现

  • 泰地唑胺AUC0-24高达90 mg*h/L时无线粒体酶基因下调,高暴露反而增加线粒体基因表达和单核细胞存活。
  • 泰地唑胺EC80的AUC0-24/MIC比值为184(CFU/mL,r2=0.96)和189(至阳性时间,r2=0.99)。
  • 泰地唑胺EC80比利奈唑胺EC80多杀灭4.0 log10 CFU/mL。
  • 泰地唑胺-莫西沙星联合的细菌负担消除速率常数为0.27±0.05/天。

临床怎么用

  • 泰地唑胺可作为儿童胞内结核的潜在替代药物,需进一步临床验证。
  • 泰地唑胺-莫西沙星联合方案可能提高杀菌效果。

局限性

  • 研究基于中空纤维系统模型,非人体临床研究。
  • 样本量及统计效能未报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Children are often neglected during early development of antituberculosis agents, and most receive treatment after it is first tested in adults. However, very young children have tuberculosis that differs in many respects from adult cavitary pneumonia and could have different toxicity profiles to drugs. Linezolid is effective against intracellular tuberculosis, a common manifestation in young children. However, linezolid has considerable toxicity due to inhibition of mitochondrial enzymes. Tedizolid could be a replacement if it shows equal efficacy and reduced toxicity. METHODS: We performed tedizolid dose-effect studies in the hollow fiber system model of intracellular tuberculosis. We measured linezolid concentrations, colony-forming units (CFU), time-to-positivity, and monocyte viability and performed RNA sequencing on infected cells collected from repetitive sampling of each system. We also compared efficacy of tedizolid vs linezolid and vs tedizolid-moxifloxacin combination. RESULTS: There was no downregulation of mitochondrial enzyme genes, with a tedizolid 0-24 hour area under the concentration-time curve (AUC0-24) of up to 90 mg*h/L. Instead, high exposures led to increased mitochondrial gene expression and monocyte survival. The AUC0-24 to minimum inhibitory concentration ratio associated with 80% of maximal bacterial kill (EC80) was 184 by CFU/mL (r2 = 0.96) and 189 by time-to-positivity (r2 = 0.99). Tedizolid EC80 killed 4.0 log10 CFU/mL higher than linezolid EC80. The tedizolid-moxifloxacin combination had a bacterial burden elimination rate constant of 0.27 ± 0.05 per day. CONCLUSIONS: Tedizolid demonstrated better efficacy than linezolid, without the mitochondrial toxicity gene or cytotoxicity signatures encountered with linezolid. Tedizolid-moxifloxacin combination had a high bacterial elimination rate.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Deshpande D, Srivastava S, Nuermberger E, et al. Multiparameter Responses to Tedizolid Monotherapy and Moxifloxacin Combination Therapy Models of Children With Intracellular Tuberculosis. Clin Infect Dis. 2018. PMID: 30496456. doi:10.1093/cid/ciy612

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。